Form 4: Axsome Therapeutics Executive Hunter R. Murdock Reports Stock Option and Restricted Stock Unit Grants

Hunter R. Murdock, General Counsel of Axsome Therapeutics, reports the acquisition of stock options and restricted stock units.

Summary

• On February 27, 2024, Hunter R. Murdock, General Counsel of Axsome Therapeutics, Inc., reported the acquisition of 23,593 stock options and 12,956 restricted stock units (RSUs).
• The stock options have an exercise price of $0.00 and vest in equal quarterly installments over four years, becoming fully vested on February 27, 2028.
• 25% of the RSUs will vest on the one-year anniversary of the grant date, with the remaining RSUs vesting in three equal annual installments, fully vesting on February 27, 2028.
• Vested shares from the RSUs will be delivered upon a Change in Control, separation of service, or seven years from the grant date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices, aligning management interests with shareholders.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedules incentivize long-term commitment from the General Counsel.

Future Outlook

The vesting schedules for the stock options and RSUs extend to February 27, 2028, indicating a long-term incentive structure.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to attract and retain key executives and align their interests with those of the shareholders.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options and RSUs to incentivize their executives.
• The vesting schedules are typical, with many companies using four-year vesting periods for equity grants.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates